KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Operating Expenses (2019 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Other Operating Expenses for 8 consecutive years, with $53.7 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 415.53% to $53.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $309.7 million through Dec 2025, up 156.68% year-over-year, with the annual reading at $309.7 million for FY2025, 156.68% up from the prior year.
  • Other Operating Expenses hit $53.7 million in Q4 2025 for CRISPR Therapeutics AG, down from $57.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $141.4 million in Q2 2025 to a low of $6.8 million in Q4 2022.
  • Historically, Other Operating Expenses has averaged $38.6 million across 5 years, with a median of $32.9 million in 2021.
  • Biggest five-year swings in Other Operating Expenses: tumbled 78.56% in 2022 and later skyrocketed 415.53% in 2025.
  • Year by year, Other Operating Expenses stood at $31.8 million in 2021, then plummeted by 78.56% to $6.8 million in 2022, then surged by 193.13% to $20.0 million in 2023, then tumbled by 47.92% to $10.4 million in 2024, then surged by 415.53% to $53.7 million in 2025.
  • Business Quant data shows Other Operating Expenses for CRSP at $53.7 million in Q4 2025, $57.1 million in Q3 2025, and $141.4 million in Q2 2025.